Blue Serenity Natural Psilocybin Panaeolus cvanescens



KEEP OUT OF REACH OF CHILDREN

Blue Serenity integrates science and compassion, creating an introspective and immersive experience capable of full spiritual enlightenment.

Important Facts

- Blue Serenity contains a total of 25 milligrams of natural psilocybin biomass, which is derived from EU-GMP Panaeolus cyanescens cultivated at Optimi's Princeton, British Columbia facility.
 - Blue Serenity will be delivered to authorized patients and practitioners in blister packs of eight (8) psilocybin capsules and is intended for use by patients granted permission to consume psilocybin under the framework of Health Canada's Special Access Program (SAP).

optimi

Blue Serenity

Proceeds from the sale of Blue Serenity will directly benefit psilocybin 3. patients through Hartle's new charity, a venture that will provide access to psilocybin therapy for underserved adults.

Hartle's Method

Designed in the tradition of Japanese art, a deep passion for Thomas, Blue Serenity integrates his sensory experience of a rock weathering a storm and the explosion of a wave crashing against a lighthouse. These visual symbols represent Thomas's psychedelic experience, one which rebuilds his mind, body and spirit and guides him to a stronger personal self.

The Natural Experience

Some patients describe the natural psilocybin experience as a gentle curve with a shorter peak and duration of 3-4 hours. This intense and therapeutic experience transitions nicely throughout the session, ending any residual feelings brought on from the overall experience.

Blue Serenity Natural Psilocybin Panaeolus cyanescens



optimi™	
Blue Serenity Natural Psilocybin	
Panaeolus cyanescens *Contains 25mg Psilocybin	000
Contents: 8 Capsules Directions for use: Oral	

Blue Serenity is packaged according to current regulations and guidelines governing the manufacture and commercial distribution of medical/pharmaceutical products (EU-GMP).

Blue Serenity will be available upon request to all legal psilocybin patients whose access has been approved by Health Canada under legal mechanisms such as SAP and Section 56 exemptions to the Controlled Drugs and Substances Act, as well as authorized researchers interested in standardized dosage of natural psilocybin.

French Version









Safe Supply Canada

Optimi is licensed by Health Canada to cultivate and supply psilocybin products to the Special Access Program, Section 56 (1) research-based studies, and authorized Clinical Trials.

Optimi is committed to furthering psilocybin education with medical associations and licensed medical practitioners around the rules governing the Special Access Program.

Blue Serenity Natural Psilocybin Panaeolus cyanescens





ABOUT THOMAS HARTLE

Thomas Hartle is a 54-year-old husband, father, and IT professional who was diagnosed with stage 4 colon cancer in 2016. Faced with the typical outcome of stage 4 cancer, Thomas experienced a debilitating level of anxiety over his future, as well as that of his family. This anxiety prompted him to explore new potential options for his treatment-resistant condition. In August of 2020, Thomas became the first Canadian to legally receive psilocybin-assisted psychotherapy.

Since that time, Thomas has experienced a substantial improvement in both his emotional wellbeing and his overall ability to once again enjoy the time he has with his family. He is currently advocating the use of this therapy while undergoing his regular cancer treatment regime.



ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company's goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi's products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin cultivator in North America.